Tranexamic Acid vs Hydroquinone for Melasma: A Complete Comparison

Tranexamic acid and hydroquinone both reduce melasma pigmentation but act at different points. Hydroquinone inhibits tyrosinase, the enzyme melanocytes use to produce melanin. Tranexamic acid works upstream, interrupting the plasmin-driven signalling that stimulates melanocytes after UV exposure and inflammation. That mechanistic difference explains why they are often combined rather than chosen between, and why relapse patterns after stopping each drug look different. This guide compares the two by mechanism, by route of administration, by evidence quality, and by the practical question patients actually face, which is what to use first and what to do when it stops working.

How Hydroquinone Works and Where It Fails

Hydroquinone is a phenolic compound that competitively inhibits tyrosinase and reduces melanosome formation. It has the longest clinical track record of any depigmenting agent and remains the reference standard against which newer treatments are measured. Its limitations are well documented. Response is typically visible after roughly eight to twelve weeks of consistent use, irritation is common at higher concentrations, and prolonged uninterrupted use carries a risk of exogenous ochronosis, a paradoxical blue-grey discolouration that is difficult to reverse. For this reason clinicians generally use it in defined cycles rather than continuously. Regulatory status differs by country; in several jurisdictions over-the-counter sale has been restricted and prescription supervision is required, which is worth confirming before travelling with or purchasing a product.

How Tranexamic Acid Works

Tranexamic acid is an antifibrinolytic agent originally used to reduce bleeding. Its effect on pigment was an incidental clinical observation that has since been investigated directly. Ultraviolet exposure activates plasminogen in keratinocytes, and the resulting plasmin increases arachidonic acid and prostaglandin signalling that stimulates melanocyte activity. By blocking plasminogen activation, tranexamic acid dampens that stimulus. It also appears to reduce the vascular component of melasma, which matters because increased dermal vascularity is a recognised feature of the condition and one reason melasma often looks worse when the skin is flushed or inflamed.

Route Matters More Than the Molecule

Oral

Oral tranexamic acid, typically dosed in the range of 250 mg twice daily in published melasma protocols, has the strongest evidence for meaningful improvement, with multiple randomised trials and meta-analyses reporting reduced melasma severity scores compared with placebo or topical treatment alone. The limiting consideration is safety screening. Because the drug is antifibrinolytic, prescribers screen for personal or family history of thrombosis, active clotting disorders, hormonal contraceptive use, smoking, and pregnancy. This is a prescription decision requiring a medical history, not a cosmetic add-on.

Topical

Topical tranexamic acid at concentrations commonly between two and five percent is widely available in cosmetic formulations and is well tolerated, but the evidence for it is weaker and less consistent than for the oral route, in part because skin penetration of the molecule is limited. It is a reasonable maintenance and adjunct option rather than a primary treatment for moderate to severe melasma.

Microinjected

Intradermal microinjection delivers the drug past the barrier and has shown benefit in several trials, though sample sizes are generally small and protocols vary. It is offered in many Korean clinics as a series of sessions. The main practical drawbacks are discomfort, cost per session, and the fact that comparative evidence against the oral route remains limited.

What Most Comparisons Miss: Melasma Is a Chronic Relapsing Condition

The framing of hydroquinone versus tranexamic acid implies a winner and a cure. Neither exists. Melasma is chronic and relapsing, driven by ultraviolet and visible light exposure, hormonal influence, and heat, and every published treatment shows recurrence after discontinuation. The clinically relevant comparison is therefore not which agent clears pigment fastest but which combination achieves clearance and which regimen a patient can sustain for years without harm. Hydroquinone is effective but cannot be used continuously. Tranexamic acid can be continued longer under supervision but requires ongoing safety consideration. This is why most contemporary protocols use hydroquinone in defined clearing cycles, tranexamic acid for suppression, and rigorous photoprotection as the permanent foundation, rather than treating either drug as a standalone answer.

Photoprotection Is Not Optional Background Advice

Visible light, not only ultraviolet, contributes to melasma in darker skin phototypes, which is why tinted sunscreens containing iron oxides are specifically recommended rather than any broad-spectrum product. Heat is an additional recognised trigger. A treatment plan that includes an effective drug and inconsistent photoprotection will underperform, and this accounts for a substantial share of apparent treatment failures. Reapplication through the day matters more than the labelled SPF figure.

Patients considering laser treatment alongside topical therapy should understand the mechanism first, and our explanation of how pico laser actually works covers why device settings matter in pigmented skin.

How Clinicians Typically Sequence Treatment

A common sequence begins with strict photoprotection plus a topical regimen, often hydroquinone alone or in a combination formulation, for a defined clearing period of roughly three months. If response is adequate, hydroquinone is tapered and maintenance shifts to non-hydroquinone agents such as topical tranexamic acid, azelaic acid, cysteamine, or a retinoid. If response is inadequate, oral tranexamic acid may be added after appropriate screening. Laser and energy devices are generally introduced later and conservatively, because aggressive settings can worsen melasma through post-inflammatory pigmentation. Sequencing decisions should be individualised by a dermatologist familiar with your skin phototype.

Frequently Asked Questions

Can I take tranexamic acid without a prescription?

Oral tranexamic acid is a prescription medicine in most countries and requires screening for clotting risk. Topical formulations are available cosmetically. Self-dosing the oral form based on internet protocols is not appropriate given the thrombotic screening involved.

How long until I see results?

Published trials generally report measurable improvement from around eight to twelve weeks with either agent, with continued gains over several months. Improvement earlier than this is uncommon, and abandoning treatment at four weeks is a frequent reason patients conclude a regimen failed.

Will my melasma come back if I stop?

Recurrence after discontinuation is common and reported across essentially all treatment modalities. Maintenance therapy and consistent photoprotection reduce but do not eliminate that likelihood.

Is hydroquinone dangerous?

Used in supervised cycles it has a long safety record. The specific concerns are irritation, unintended lightening of surrounding skin, and exogenous ochronosis with prolonged uninterrupted high-concentration use. These risks are the reason for cycling rather than continuous use.

Can the two be used together?

Combination approaches are common in clinical practice and several studies report better outcomes with combined regimens than with either alone. The specific combination and duration should be set by a treating physician.

Talking to Your Dermatologist

Bring photographs taken in consistent lighting over time, a full list of current medications including hormonal contraception, and an honest account of your sun exposure and daily photoprotection habit. Melasma treatment decisions depend heavily on that history. The information here is general and educational; diagnosis and prescribing must come from a licensed physician who has examined your skin.